Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for PENG Block on Post Operative Pain Management in Patients Undergoing Hip Arthroplasty
NCT06565910Phase 4Recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of liposomal bupivacaine in postoperative pain (2 arms), sponsored by Huazhong University of Science and Technology. Primary endpoint: Overall Opioid Consumption at 72 hours. Started Dec 2024; status: recruiting.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06565910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06565910.